JP2023504115A5 - - Google Patents

Info

Publication number
JP2023504115A5
JP2023504115A5 JP2022531531A JP2022531531A JP2023504115A5 JP 2023504115 A5 JP2023504115 A5 JP 2023504115A5 JP 2022531531 A JP2022531531 A JP 2022531531A JP 2022531531 A JP2022531531 A JP 2022531531A JP 2023504115 A5 JP2023504115 A5 JP 2023504115A5
Authority
JP
Japan
Prior art keywords
agent according
approximately
tadalafil
selexipag
macitentan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022531531A
Other languages
English (en)
Japanese (ja)
Other versions
JP7721520B2 (ja
JP2023504115A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/083593 external-priority patent/WO2021105331A1/en
Publication of JP2023504115A publication Critical patent/JP2023504115A/ja
Publication of JP2023504115A5 publication Critical patent/JP2023504115A5/ja
Priority to JP2024118344A priority Critical patent/JP7620758B2/ja
Priority to JP2025127467A priority patent/JP2025172745A/ja
Application granted granted Critical
Publication of JP7721520B2 publication Critical patent/JP7721520B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022531531A 2019-11-29 2020-11-27 肺動脈性肺高血圧症の治療方法 Active JP7721520B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024118344A JP7620758B2 (ja) 2019-11-29 2024-07-24 肺動脈性肺高血圧症の治療方法
JP2025127467A JP2025172745A (ja) 2019-11-29 2025-07-30 肺動脈性肺高血圧症の治療方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962941910P 2019-11-29 2019-11-29
US62/941,910 2019-11-29
US202063023452P 2020-05-12 2020-05-12
US63/023,452 2020-05-12
US202063076149P 2020-09-09 2020-09-09
US63/076,149 2020-09-09
PCT/EP2020/083593 WO2021105331A1 (en) 2019-11-29 2020-11-27 Methods of treating pulmonary arterial hypertension

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2024118344A Division JP7620758B2 (ja) 2019-11-29 2024-07-24 肺動脈性肺高血圧症の治療方法
JP2025127467A Division JP2025172745A (ja) 2019-11-29 2025-07-30 肺動脈性肺高血圧症の治療方法

Publications (3)

Publication Number Publication Date
JP2023504115A JP2023504115A (ja) 2023-02-01
JP2023504115A5 true JP2023504115A5 (cg-RX-API-DMAC10.html) 2023-12-04
JP7721520B2 JP7721520B2 (ja) 2025-08-12

Family

ID=73726769

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022531531A Active JP7721520B2 (ja) 2019-11-29 2020-11-27 肺動脈性肺高血圧症の治療方法
JP2024118344A Active JP7620758B2 (ja) 2019-11-29 2024-07-24 肺動脈性肺高血圧症の治療方法
JP2025127467A Pending JP2025172745A (ja) 2019-11-29 2025-07-30 肺動脈性肺高血圧症の治療方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024118344A Active JP7620758B2 (ja) 2019-11-29 2024-07-24 肺動脈性肺高血圧症の治療方法
JP2025127467A Pending JP2025172745A (ja) 2019-11-29 2025-07-30 肺動脈性肺高血圧症の治療方法

Country Status (18)

Country Link
US (1) US12485119B2 (cg-RX-API-DMAC10.html)
EP (1) EP4065119B1 (cg-RX-API-DMAC10.html)
JP (3) JP7721520B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220106974A (cg-RX-API-DMAC10.html)
CN (1) CN114728002A (cg-RX-API-DMAC10.html)
AU (1) AU2020392424A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022010311A2 (cg-RX-API-DMAC10.html)
CA (1) CA3158292A1 (cg-RX-API-DMAC10.html)
CR (1) CR20220305A (cg-RX-API-DMAC10.html)
EC (1) ECSP22051163A (cg-RX-API-DMAC10.html)
ES (1) ES2994089T3 (cg-RX-API-DMAC10.html)
IL (1) IL293271A (cg-RX-API-DMAC10.html)
JO (1) JOP20220127A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022006403A (cg-RX-API-DMAC10.html)
PE (1) PE20221320A1 (cg-RX-API-DMAC10.html)
PH (1) PH12022551294A1 (cg-RX-API-DMAC10.html)
TW (1) TW202133851A (cg-RX-API-DMAC10.html)
WO (1) WO2021105331A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024099953A1 (en) * 2022-11-07 2024-05-16 Actelion Pharmaceuticals Ltd Combination of macitentan and tadalafil for the treatment of pulmonary arterial hypertension
KR102663470B1 (ko) * 2023-03-16 2024-05-10 주식회사 케어사이드 폐성 고혈압에 의한 심장 질환 예방 및 심장 치료용 조성물 및 이를 포함하는 기능성 제제

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1693372A1 (en) 2000-12-18 2006-08-23 Actelion Pharmaceuticals Ltd. Novel Sulfamides and their use as endothelin receptor antagonists
TWI316055B (cg-RX-API-DMAC10.html) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
ES2393117T3 (es) 2005-09-12 2012-12-18 Actelion Pharmaceuticals Ltd. Composición farmacéutica estable que comprende una pirimidina-sulfamida
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
MX350011B (es) 2008-08-13 2017-08-22 Actelion Pharmaceuticals Ltd Composiciones terapeuticas que contienen macitentan.
SG176915A1 (en) 2009-06-26 2012-01-30 Nippon Shinyaku Co Ltd Crystals
WO2011024874A1 (ja) 2009-08-26 2011-03-03 日本新薬株式会社 塩基付加塩
EA026074B1 (ru) 2010-10-15 2017-02-28 Джилид Сайэнс, Инк. Способы, включающие применение композиции амбризентана и тадалафила для лечения легочной артериальной гипертензии
CN106461677B (zh) * 2014-04-22 2018-09-11 国立大学法人东北大学 肺高血压病的检查方法
AU2016207046B2 (en) * 2015-01-13 2021-04-01 Vivus Llc Combination therapy for pulmonary hypertension
RU2763525C2 (ru) * 2016-10-27 2021-12-30 Пульмокин, Инк. Комбинированная терапия для лечения легочной гипертензии
EP3897646B1 (en) * 2018-12-21 2024-05-22 Actelion Pharmaceuticals Ltd Macitentan for the treatment of pulmonary arterial hypertension

Similar Documents

Publication Publication Date Title
CN1547464B (zh) 缓释治疗性生物粘附系统
JP2020529996A5 (cg-RX-API-DMAC10.html)
EP4633616A1 (en) Irak4 degraders and uses thereof
CN100594936C (zh) 改善透粘膜给药制剂的吸收的方法
De Zeeuw et al. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment.
CN113018273A (zh) 一种固体制剂及其制备方法和用途
JP2024523559A5 (cg-RX-API-DMAC10.html)
JP7343478B2 (ja) 処置の方法
JPH0667842B2 (ja) 基本的うつ病を軽減するためのうつ病治療剤
JP2022031527A (ja) ピルフェニドンの粒子の大きさ調節による打錠性が改善された薬剤学的組成物およびその製造方法
TWI783921B (zh) 手部溼疹之治療
JP2025504219A5 (cg-RX-API-DMAC10.html)
JP2022177119A5 (cg-RX-API-DMAC10.html)
EP2509586B1 (en) Mucoadhesive buccal tablets for the treatment of orofacial herpes
MX2013005716A (es) Formulacion de un complejo que comprende clorhidrato de lercanidipina y valsartan y metodo para la preparacion de la misma.
EP4344701A1 (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
EP2535048A1 (en) Extended release preparation
EP1465607B1 (fr) Compositions pharmaceutiques a liberation modifiee
WO2018028841A1 (en) Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
JP2002531495A (ja) ウイルス疾患を処置するためのビュープロピオン
CN107205987A (zh) 根据auc进行奥美沙坦给药的方法
JP2022550458A5 (cg-RX-API-DMAC10.html)
US20240415814A1 (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
JP3002766B2 (ja) 脳浮腫治療剤
WO2018129463A1 (en) Co-administration of minocycline and colistin to reduce acute kidney injury